|Expression of PPARγ, p27 and Ki67 in Cervical Cancer and its Clinical Significance
|LI Peng-li1, TAN Hai-zhi2
|1. Department of Obstetrics and Gynecology, Funing County Hospital of TCM, Qinhuangdao, Hebei, 066300, China;
2. School of Medicine, Chengdu University of TCM, Chengdu, Sichuan, 611137, China.
| 1 de Freitas AC, Gomes Leitao Mda C, Coimbra EC. Prospects of molecularly-targeted therapies for cervical cancer treatment. Curr Drug Targets, 2015, 16(1): 77-91.
2 Chhabra R. Cervical cancer stem cells: opportunities and challenges. J Cancer Res Clin Oncol, 2015, [Epub ahead of print].
3 Foppoli C, De Marco F, Cini C, et al. Redox control of viral carcinogenesis: The human papillomavirus paradigm. Biochim Biophys Acta, 2014, [Epub ahead of print].
4 Campisi G, Panzarella V, Giuliani M, et al. Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions. Int J Oncol, 2007, 30(4): 813-23.
5 Liu X, Yang WT, Zheng PS. Msi1 promotes tumor growth and cell proliferation by targeting cell cycle checkpoint proteins p21, p27 and p53 in cervical carcinomas. Oncotarget, 2014, 5(21): 10870-85.
6 Jung TI, Baek WK, Suh SI, et al. Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma. Gynecol Oncol, 2005, 97(2): 365-73.
7 Wu CW, Yu J, Sung JJ. Peroxisome proliferator-activated receptor delta and gastric cancer. Oncol Rep, 2009, 22(3): 451-7.
8 Janani C, Ranjitha Kumari BD. PPAR gamma gene - A review. Diabetes Metab Syndr, 2015, 9(1): 46-50.
9 Fenner MH, Elstner E. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opin Investig Drugs, 2005, 14(6): 557-68.
10 Liu S, Lin SJ, Li G1, et al. Differential roles of PPARγ vs TR4 in prostate cancer and metabolic diseases. Endocr Relat Cancer, 2014, 21(3): R279-300.
11 Nam DH, Ramachandran S, Song DK, et al. Growth inhibition and apoptosis induced in human leiomyoma cells by treatment with the PPAR gamma ligand ciglitizone. Mol Hum Reprod, 2007, 13(11): 829-36.
12 Nikhil K, Sharan S, Singh AK, et al. Anticancer activities of pterostilbene-isothiocyanate conjugate in breast cancer cells: involvement of PPARγ. PLoS One, 2014, 9(8): e104592.
13 Fukuoka T, Yashiro M, Morisaki T, et al. The role of type D prostanoid receptors and PPARγ in gastric cancer progression. Anticancer Res, 2014, 34(6): 2771-8.
14 Zurlo D, Assante G, Moricca S, et al. Cladosporol A, a new peroxisome proliferator-activated receptor γ (PPARγ) ligand, inhibits colorectal cancer cells proliferation through β-catenin/TCF pathway inactivation. Biochim Biophys Acta, 1840(7): 2361-72.
15 Reddi HV, Driscoll CB, Madde P, et al. Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARγ fusion proteininhibits anaplastic thyroid cancer: a novel therapeutic strategy. Cancer Gene Ther, 2013, 20(5): 267-75.
16 Du Y, Wang L, Si S, et al. A novel compound 4010B-30 upregulates apolipoprotein A-I gene expression through activation of PPARγ in HepG2 cells. Atherosclerosis, 2015, 239(2): 589-98.
17 Reddi HV, Madde P, Milosevic D, et al. The Putative PAX8/PPARγ Fusion Oncoprotein Exhibits Partial Tumor Suppressor Activity through Up-Regulation of MicroRNA-122 and Dominant-Negative PPARγ Activity. Genes Cancer, 2011, 2(1): 46-55.
18 Ramasubramanian A, Ramani P, Sherlin HJ, et al. Immunohistochemical evaluation of oral epithelial dysplasia using cyclin-D1, p27 and p63 expression as predictors of malignant transformation. J Nat Sci Biol Med, 2013, 4(2): 349-58.
19 Gao L, Gu W, Zheng J, et al. Clinicopathological and prognostic significance of p27 expression in oral squamous cell carcinoma: a meta-analysis. Int J Biol Markers, 2013, 28(4): e329-35.
20 Roy A, Banerjee S. p27 and leukemia: cell cycle and beyond. J Cell Physiol, 2015, 230(3): 504-9.
21 Lloyd RV, Erickson LA, Jin L, et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol, 1999, 154(2): 313-23.
22 Bhatia B, Malik A, Fernandez-LA, et al. p27(Kip1), a double-edged sword in Shh-mediated medulloblastoma: Tumor accelerator and suppressor. Cell Cycle, 2010, 9(21): 4307-14.
23 Zhao YF, Zhao JY, Yue H, et al. FOXD1 promotes breast cancer proliferation and chemotherapeutic drug resistance by targeting p27. Biochem Biophys Res Commun, 2015, 456(1): 232-7.
24 Ogino S, Shima K, Nosho K, et al. A cohort study of p27 localization in colon cancer, body mass index, and patient survival. Cancer Epidemiol Biomarkers Prev, 2009, 18(6): 1849-58.
25 Jain AK, Raina K, Agarwal R. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model. Cell Cycle, 2013, 12(10): 1598-604.
26 He W, Wang X, Chen L, et al. A crosstalk imbalance between p27(Kip1) and its interacting molecules enhances breast carcinogenesis. Cancer Biother Radiopharm, 2012, 27(7): 399-402.
27 Wander SA, Zhao D, Slingerland JM. p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clin Cancer Res, 2011, 17(1): 12-8.
28 Bouda J, Hes O, Koprivova M, et al. P27 as a prognostic factor of early cervical carcinoma. Int J Gynecol Cancer, 2013, 23(1): 164-9.
29 Goff BA, Sallin J, Garcia R, et al. Evaluation of p27 in preinvasive and invasive malignancies of the cervix. Gynecol Oncol, 2003, 88(1): 40-4.
30 Kim JY, Lim SJ, Kim HJ, et al. Clinical significance of p27 and Skp2 protein expression in uterine cervical neoplasm. Int J Gynecol Pathol, 2007, 26(3): 242-7.
31 Sgambato A, Zannoni GF, Faraglia B, et al. Decreased expression of the CDK inhibitor p27Kip1 and increased oxidative DNA damage in the multistep process of cervical arcinogenesis. Gynecol Oncol, 2004, 92(3): 776-83.
32 Chen TP, Chen CM, Chang HW, et al. Increased expression of SKP2 and phospho-MAPK/ERK1/2 and decreased expression of p27 during tumor progression of cervical neoplasms. Gynecol Oncol, 2007, 104(3): 516-23.
33 Huang LW, Seow KM, Lee CC, et al. Decreased p21 expression in HPV-18 positive cervical carcinomas. Pathol Oncol Res, 2010, 16(1): 81-6.
34 Alfsen GC, Reed W, Sandstad B, et al. The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma. Cancer, 2003, 98(9): 1880-9.
35 Zhou Y, Jiang HG, Lu N, et al. Expression of ki67 in papillary thyroid microcarcinoma and its clinical significance. Asian Pac J Cancer Prev, 2015, 16(4): 1605-8.
36 Li LT, Jiang G, Chen Q, et al. Ki67 is a promising molecular target in the diagnosis of cancer. Mol Med Rep, 2015, 11(3): 1566-72.
37 Kontzoglou K, Palla V, Karaolanis G, et al. Correlation between Ki67 and breast cancer prognosis. Oncology, 2013, 84(4): 219-25.
||TAN Mi-duo. Research Progress of Translational Medicine in Breast Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 86-91.
||Lukas Gietz, Benjamin Mayer. A Resampling Approach for Sample Size Estimation in Animal Experiments[J]. Journal of International Translational Medicine, 2017, 5(2): 53-62.
||QIAN Ting, HUANG Xin-en. Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 63-66.
||MAO Xiao-dong, ZHE Yi, CHEN Ya-jun, LIU Kang-sheng. Detection of Serum Anti-Müllerian Hormone Level for Women of Reproductive Age: A Cross-Sectional Study[J]. Journal of International Translational Medicine, 2017, 5(2): 67-70.
||LIU Yong-jun, ZHOU Yan. Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy[J]. Journal of International Translational Medicine, 2017, 5(2): 80-85.
||WANG Peng. Chimeric Antigen Receptor-Engineered T Cells in Tumor Immunotherapy: From Bench to Beside[J]. Journal of International Translational Medicine, 2017, 5(2): 92-97.